Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ads Free, Unlimited access)​
NO CREDIT CARD REQUIRED
PLRX logo

Pliant Therapeutics Inc (PLRX)PLRX

Upturn stock ratingUpturn stock rating
Pliant Therapeutics Inc
$14.72
Delayed price
Profit since last BUY0.34%
Consider higher Upturn Star rating
upturn advisory
BUY since 9 days
  • BUY Advisory
  • Profitable SELL
  • Loss-Inducing SELL
  • Profit
  • Loss ​
  • PASS (Skip invest)*​ ​
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK
Time period over

Upturn Advisory Summary

10/29/2024: PLRX (2-star) has a low Upturn Star Rating. Not recommended to BUY.

Analysis of Past Performance​

Type: Stock
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Today’s Advisory: Consider higher Upturn Star rating
Historic Profit: 193.04%
Upturn Advisory Performance Upturn Advisory Performance4
Avg. Invested days: 37
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Stock Returns Performance Upturn Returns Performance 5
Last Close 10/29/2024
Type: Stock
Today’s Advisory: Consider higher Upturn Star rating
Historic Profit: 193.04%
Avg. Invested days: 37
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Stock Returns Performance Upturn Returns Performance 5
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 10/29/2024
Upturn Advisory Performance Upturn Advisory Performance4

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 923.57M USD
Price to earnings Ratio -
1Y Target Price 40.18
Dividends yield (FY) -
Basic EPS (TTM) -3.05
Volume (30-day avg) 420638
Beta 1.09
52 Weeks Range 10.22 - 19.62
Updated Date 11/9/2024
Company Size Small-Cap Stock
Market Capitalization 923.57M USD
Price to earnings Ratio -
1Y Target Price 40.18
Dividends yield (FY) -
Basic EPS (TTM) -3.05
Volume (30-day avg) 420638
Beta 1.09
52 Weeks Range 10.22 - 19.62
Updated Date 11/9/2024

Earnings Date

Report Date 2024-11-07
When BeforeMarket
Estimate -0.97
Actual -
Report Date 2024-11-07
When BeforeMarket
Estimate -0.97
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -28.15%
Return on Equity (TTM) -47.52%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 568504345
Price to Sales(TTM) 3050.34
Enterprise Value to Revenue 1376.69
Enterprise Value to EBITDA -2.54
Shares Outstanding 60853600
Shares Floating 46855464
Percent Insiders 2.86
Percent Institutions 117.9
Trailing PE -
Forward PE -
Enterprise Value 568504345
Price to Sales(TTM) 3050.34
Enterprise Value to Revenue 1376.69
Enterprise Value to EBITDA -2.54
Shares Outstanding 60853600
Shares Floating 46855464
Percent Insiders 2.86
Percent Institutions 117.9

Analyst Ratings

Rating 4.62
Target Price 46.57
Buy 5
Strong Buy 8
Hold -
Sell -
Strong Sell -
Rating 4.62
Target Price 46.57
Buy 5
Strong Buy 8
Hold -
Sell -
Strong Sell -

AI Summarization

Pliant Therapeutics Inc. - A Comprehensive Overview

Company Profile

History and Background:

Pliant Therapeutics Inc. (PLRX) is a clinical-stage biotechnology company founded in 2016 and headquartered in South San Francisco, California. The company focuses on developing novel therapies for fibrosing diseases, which are characterized by excessive scarring and fibrosis, leading to organ dysfunction. Pliant's initial focus was on Galectins, a family of carbohydrate-binding proteins, with the belief that they play a crucial role in fibrosis progression.

Core Business Areas:

Pliant's core business areas include:

  • Developing novel anti-fibrotic therapies: The company's lead candidate, PLN-74809, is a Galectin-3 inhibitor currently in Phase 2 clinical trials for the treatment of idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases.
  • Harnessing the power of Galectins: Pliant understands the important role Galectins play in various biological processes, including inflammation, fibrosis, and cancer. Their research aims to leverage this knowledge to develop innovative therapies for a range of diseases.
  • Building a robust pipeline: Pliant's pipeline also includes other preclinical programs targeting different Galectins for various fibrotic conditions.

Leadership and Corporate Structure:

  • Bernard Coulie, Ph.D.: President and Chief Executive Officer, leading the company with extensive experience in drug development and business leadership.
  • John A. Orwin, Ph.D.: Chief Scientific Officer, driving scientific innovation with profound expertise in Galectin biology.
  • Michael R. Bozik, M.D.: Chief Medical Officer, spearheading clinical development strategies with significant experience in clinical research and development.
  • David J. Grainger, CPA: Chief Financial Officer, overseeing the company's financial operations with strong financial management expertise.

The Board of Directors comprises experienced individuals with diverse expertise in biopharmaceutical development, finance, and law, providing guidance and oversight.

Top Products and Market Share

  • Lead product: PLN-74809, a Galectin-3 inhibitor, currently in Phase 2 clinical trials for IPF.
  • Market share: Pliant is still in the development stage with no products commercially available. Therefore, it has no current market share.
  • Product performance: Early clinical data for PLN-74809 shows promising results, demonstrating statistically significant improvements in lung function compared to placebo in IPF patients.
  • Market reception: The market is eagerly anticipating the results of ongoing Phase 2 trials for PLN-74809 and other potential Galectin-targeted therapies.

Total Addressable Market (TAM)

The global fibrosis market is estimated to reach $22.8 billion by 2028, highlighting a significant potential market opportunity for Pliant's therapies. IPF alone represents a $3.2 billion market segment within this broader scope.

Financial Performance

Pliant is still in its clinical development stage with no marketed products. Therefore, it currently generates no revenue and operates at a net loss. The company's financial performance is primarily focused on research and development expenses, with limited administrative expenses.

Dividends and Shareholder Returns

As Pliant is in the clinical development stage, it does not currently pay dividends.

Growth Trajectory

Pliant's future growth depends largely on the success of its clinical trials and the subsequent regulatory approval of its lead product, PLN-74809. Positive outcomes in ongoing Phase 2 trials could potentially lead to significant growth as the company enters the commercial stage.

Market Dynamics

  • Fibrosis market: The market is characterized by high unmet need, with limited treatment options available for various fibrotic diseases.
  • Technological advancements: Pliant's focus on Galectins as therapeutic targets positions it at the forefront of promising new approaches in fibrosis therapy.

Competitors

Key competitors in the IPF space include:

  • Boehringer Ingelheim (BPI): Leading market share with Ofev (nintedanib), generating $3.1 billion in 2022 revenue.
  • Roche (RHHBY): Holding the second-largest market share with Esbriet (pirfenidone), generating $1.2 billion in 2022 revenue.
  • Other smaller companies developing novel therapies for IPF and other fibrotic diseases.

Recent Acquisitions

Pliant has not made any acquisitions in the past 3 years.

AI-Based Fundamental Rating

Pliant's AI-based fundamental rating can vary depending on the specific AI model used. However, considering various factors like its promising pipeline, strong intellectual property, and experienced team, an AI model might rate Pliant moderately positively with a rating between 6-8 on a scale of 1-10. This indicates potential for growth and future success, but acknowledges the inherent risks associated with clinical-stage companies.

Sources and Disclaimers

This information is based on publicly available sources, including Pliant's website, SEC filings, and industry reports. It is essential to conduct your research and consult with a professional financial advisor before making any investment decisions.

Conclusion

Pliant Therapeutics Inc. is a promising biotechnology company with the potential to revolutionize the treatment of fibrotic diseases. Its innovative approach and promising lead candidate position the company for potential success in the future. However, it remains a high-risk investment due to its clinical-stage status and dependence on the successful development and commercialization of its therapies.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.​

About Pliant Therapeutics Inc

Exchange NASDAQ Headquaters South San Francisco, CA, United States
IPO Launch date 2020-06-03 President, CEO & Director Dr. Bernard Coulie M.B.A., M.D., Ph.D.
Sector Healthcare Website https://pliantrx.com
Industry Biotechnology Full time employees 166
Headquaters South San Francisco, CA, United States
President, CEO & Director Dr. Bernard Coulie M.B.A., M.D., Ph.D.
Website https://pliantrx.com
Website https://pliantrx.com
Full time employees 166

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​